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Angiotensin II ( ang II) is a vasoactive hormone derived from the renin 
angiotensin system (RAS), which regulates blood pressure and fluid balance in the body. 
Ang II effects are mediated via two major receptors: type 1 (AT 1) and type 2 (AT 2). 
Adipocytes contain a local RAS in which ang II upregulates adipogenesis, fatty acid and 
triglyceride synthesis primarily mediated via the AT 2 receptor in cultured adipocytes. 
Preliminary studies from our lab tested the importance of AT 2 receptors in vivo and 
reported a decrease in adiposity by AT 2 antagonism in the lean, but not the genetically 
obese db/db mouse. To further explore these effects, we used another genetic model of 
obesity (ob/ob) and diet-induced obese (DIO) mice and treated them for 2-3 weeks with 
the AT 2 receptor antagonist, PD 123,319. Body weight, fat pad weight and plasma 
glucose, leptin and insulin levels and fatty acid synthase (FAS) and glycerol-3-phosphate 
dehydrogenase (GPDH) activity were measured. Consistent with previous findings in 
lean mice, the AT 2 antagonist decreased abdominal fat pad weight in ob/ob mice and 
accelerated weight loss in D10 mice. Also, correlated with these effects, AT2 blockade 
decreased FAS activity in ob/ob mice and lowered blood glucose levels in DIO mice. No 
significant changes were seen in the other parameters that were measured. In 
combination with recently published data, this research further supports the role of the 
AT 2 receptor in modulating ang II effects on adipocyte metabolism. Defining this role is 
crucial in determining and preventing the contribution of adipocyte-derived RAS to 
systemic disorders such as obesity-related hypertension. 
TABLE OF CONTENTS 
Chapter 
I. INTRODUCTION .................................................................. 1 
II. LITERATURE REVIEW ......................................................... 2 
Obesity and Hypertension ........................................................... 2 
Obesity ........................................................................ 2 
Hypertension ................................................................. 5 
Obesity-related hypertension .............................................. 7 
Adipose tissue physiology ................................................. 7 
Renin-Angiotensin System (RAS) ................................................ 8 
Systemic RAS ............................................................... 8 
RAS-related hypertension ................................................. 9 
Ang II receptors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 
Adipose Tissue RAS ................................................................. 14 
Regulation of RAS .......................................................... 15 
Effects of RAS ............................................................... 16 
III. EXPERIMENTAL SECTION: DIFFERENTIAL EFFECTS 
OF ANGIOTENSIN II TYPE 2 RECEPTOR ANTAGONISM 
ON ADIPOSITY IN MICE MODELS OF OBESITY ...................... 20 
Introduction ........................................................................... 20 
Research Objectives .................................................................. 21 
Experimental Design and Approach ............................................... 22 
Animals ....................................................................... 22 
Primary culture of adipocytes ............................................. 26 
Glucose ....................................................................... 27 
Leptin and insulin radioimmunoassay .................................... 27 
FAS and GPDH assays ..................................................... 28 
Protein assay ................................................................. 28 
RNA isolation ............................................................... 29 
Real time PCR ............................................................... 29 
Statistical analysis .......................................................... 30 
Results ................................................................................. 31 
Effects of ang II antagonism in ob/ob mice .............................. 31 
Effects of ang II antagonism in DIO 1 mice maintained 
on chow diet .................................................................. 31 
Effects of ang II antagonism in DIO2 mice maintained 
on high-fat diet ............................................................... 31 
Effects of ang II and PD in primary adipocytes ......................... 38 
Discussion ............................................................................. 38 
V 
VI 
Summary and Conclusions ......................................................... 43 
LIST OF REFERENCES ................................................................... 46 
APPENDIX .................................................................................... 58 
VITA ........................................................................................... 6 1  
LIST OF FIGURES 
Figure Page 
1. R A S  and its biological effects ...................................................... 10 
2. Antagonism of R A S  .................................................................. 1 2  
3. Summary of ang II effects in adipose tissue via the AT  2 
receptor. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I 7 
4. Summary of endocrine and paracrine effects of adipose 
tissue on blood pressure ............................................................. 18 
5. Overview of the experimental design of animal studies ........................ 25 
6. Effects of AT2 receptor antagonism on abdominal fat pad weight 
and FAS  activity in ob/ob mice .................................................... 33 
7. Change in body weight of ob/ob mice over course of treatment.. ............. 3 4  
8. Change in body weight ofDI Ol mice over course of treatment ............... 36 
9. Change in body weight ofDI O2  mice over course oftreatment ............... 37 
10. Effects of ang II antagonists on food intake in D1 O2  mice ..................... 40 
1 1. Contribution of adipocyte ang II to obesity and hypertension ................. .4 5 
Vll 
Vlll 
LIST OF TABLES 
1. Classification of Overweight and Obesity by BMI .............................. 2 
2. Genetic mutations resulting in obesity ............................................. 5 
3. Classification of Blood Pressure for Adults ( 21. 8years of age) ................ 6 
4. Summary of the main functions of AT 1 and AT 2 receptors ..................... 1 4  
5. Current research on ang II receptor expression in adipose tissue .............. 1 9  
6. Cycles of real time P C R  ............................................................. 30 
7. Effects of ang II antagonism in ob/ob mice ....................................... 3 2  
8. Effects of ang II antagonists in D1O 1  mice ........................................ 3 5  
9. Effects of ang II antagonism in D1 O2  mice ....................................... 3 9  
10. Effects of ang II and PD on leptin levels secreted from 





















LIST OF ABREVIATIONS 
Angiotensin 
Angiotensin II type 1 receptor 
Angiotensin II type 2 receptor 
Angiotensin Converting Enzyme 
Angiotensinogen 
Body mass index 
Bovine serum albumin 
Diet-induced obesity, study #1 
Diet-induced obesity, study #2 
Fatty acid synthase 
Fetal bovine serum 
Glycerol-3-phosphate dehydrogenase 
Guanosine triphosphate 
Nicotinamide adenine dinucleotide (reduced form) 
Nicotinamide adenine dinucleotide phosphate (reduced form) 
Phosphate buffered saline 
PD 123,319, AT 2 antagonist 
Prostacyclin 






Sixty-one percent of the adult population in the United States is overweight or 
obese (1 ). This growing number has major public health implications. There are many 
chronic health conditions associated with obesity, such as type 2 diabetes, cardiovascular 
disease and hypertension (2,3). The increasing prevalence of these and other obesity­
related health risks emphasizes the need for understanding the pathogenesis of obesity. 
This will allow us to better prevent and treat obesity as a condition and prevent these 
associated diseases. 
Obesity is a disease characterized by excessive accumulation of adipose tissue in 
the body (4). While adipose tissue was once thought of as only a storage depot for 
triglycerides, it is now known to also function as a paracrine and endocrine organ ( 5). 
The paracrine function of adipocytes includes regulation of adipose tissue metabolism 
and gene expression ( 6). The endocrine function of adipose tissue includes systemic 
effects on blood pressure and kidney homeostasis. 
The renin-angiotensin system (RAS) is the major regulator of blood pressure, 
fluid and electrolyte balance (7). A local RAS has been identified in adipose tissue (8). 
The purpose of this study is to determine how the end product of RAS, angiotensin II, 





Obesity and Hypertension 
The combined prevalence of overweight and obesity among men and women 
between the ages of 20 and 80 is 61 percent (1,9). Not only is the majority of our adults 
overweight or obese, but the number of children and adolescents with obesity and type II 
diabetes is also increasing (1 ). 
There are several ways to estimate body fat. One of the easiest, most affordable 
and least invasive ways is body mass index (BMI). The National Institutes of Health 
recommend physicians use BMI when assessing overweight and obesity (Table 1) (2). 
BMI is defined as weight (in kg) divided by height in meters squared (in m2). 
Table 1. Classification of Overweight and Obesity by BMI. 
Obesity Class BMI (kg/m2) 
Underweight < 18.5 
Normal 18.5 - 24.9 
Overweight 25.0 - 29.9 
Obesity I 30.0 - 34.9 
II 35.0 - 39.9 
Extreme Obesity III 2:40 
Health professionals agree that an increase in body weight of twenty percent or 
more is considered a health hazard (10). Health risks of overweight and obesity include 
(1-3): 
■ Hypertension 
■ Type 2 diabetes 
• Coronary heart disease 
■ Stroke 
■ Dyslipidemia 
■ Gallbladder disease 
• Osteoarthritis 
■ Sleep apnea and respiratory problems 
■ Certain types of cancers 
Hypertension, hypercholesterolemia (blood cholesterol over 250 mg/dL) and diabetes 
(blood glucose over 126 mg/dL) are more than twice as prevalent in overweight vs. non­
overweight individuals ( 10). 
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Obesity is a complex and multi-factorial disorder. Genetics, lifestyle and 
endocrine disorders all contribute to the epidemic of obesity (1,4,11). The importance of 
heredity was shown in a study by Stunkard et al. (12) that found the BMI of adopted 
children strongly correlated with the BMis of their biological family members and did 
not correlate with the BM Is of their adoptive family. Studies such as this one and others 
by Bouchard et al. (13,14) demonstrate the importance of genetics in the pathogenesis 
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and etiology of obesity. Researchers are presently working to link the obese phenotype 
to the responsible genes. 
Lifestyle is a major determinant of obesity, the two main factors being food intake 
and physical activity (15). Western lifestyle has changed the energy balance for many 
Americans by increasing caloric intake and decreasing physical activity. In many cases 
these environmental factors will exacerbate an existing genetic disposition towards 
obesity (2). 
Obesity due to genetic defects is very rare, but genetic syndromes such as Prader­
Willi, Cohen, Borjeson-Forssman-Lehmann that have been identified to cause obesity as 
well as other endocrine dysfunctions (16, 17). Prader-Willi syndrome, for example, is 
caused by the deletion of multiple genes in close proximity on chromosome fifteen 
(18, 19). Among other symptoms, a hypothalamic dysfunction causes extreme 
hyperphagia (19). This disordered eating is compounded by decreased energy utilization, 
making these individuals morbidly obese (20). 
While obesity mutations are rare in humans, many animal models of obesity have 
been developed based on single gene mutations. Table 2 gives a summary of some major 
obesity genes and their effects (11,21-23). 
Two mouse mutations commonly used in research are the db/db and ob/ob. The 
db/db mouse has a mutation in the gene coding for the leptin receptor while the ob/ob 
mouse is leptin-deficient (21 ). Both cause similar phenotypes in mice (23 ). These 
animals have severe juvenile-onset obesity and exhibit reduced basal metabolic rate, 
Table 2. Genetic mutations resulting in obesity. 
Mutation Gene product Rodent Human effects of chromosome chromosome mutation 
agouti yellow agouti signaling ubiquitous 
(A>') protein 
2 20 over-expression 
of agouti 
obese (ob) leptin 6 7 deficiency of leptin 
diabetes (db) leptin receptor 4 1 defect in leptin signal 
fat (fat) carbox ypeptidase E 8 4 
processing of 
prehormone 
tubby (tub) insulin signaling 7 1 1  undefined protein 
h yperphagia, h yperinsulinemia, insulin resistance, glucose intolerance and diabetes 
( 1 1,22,23). 
Hypertension 
H ypertension is defined as high blood pressure that remains elevated over time 
(Table 3) (24,25). It is caused by narrowing of the arteries, greater than normal amount 
of blood or the heart beating faster and more forcefully than normal (24). H ypertension 
increases stress on the heart and contributes to atheriosclerosis and increases the risk of 
heart disease and stroke. 
Approximately 50 million adult Americans have high blood pressure and it is 
more common in African Americans and in the elderly (> 60 years of age) (24). 
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Table 3. Classification of Blood Pressure for Adults ( 2: 18 years of age). 
Systolic and/or Diastolic 
(mm Hg) 
Optimal <1 20 and <80 
Normal <130 and <85 
High-normal 130-13 9 or 85-89 
Hypertension 
Stage 1 1 40-1 5 9  or 90- 9 9  
Stage 2 160-17 9 or 100-10 9 
Stage 3 2: 180 or 2: 110 
Individuals who have a high-normal blood pressure are also at risk for hypertension (26). 
Others at risk for hypertension are people who are overweight or have a family history of 
high blood pressure (24, 25). 
Hypertension rates are correlated among family members (27), however the 
disease is also multi-factorial. It appears to be polygenic and influenced by the 
environment (28). 
Health risks associated with hypertension include heart disease, stroke, congestive 
heart failure, kidney disease and blindness (24, 25). Hypertension can be prevented or 
controlled by the following lifestyle modifications (24, 25): 
■ Maintaining a healthy weight 
■ Following a healthy eating pattern 
■ Being physically active 
■ Reducing salt and sodium in the diet 
• Maintaining adequate intakes of potassium, calcium and 
magnesium 
• Limiting alcohol intake 
• Quitting smoking 
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Another option for controlling hypertension is pharmacological interventions, which will 
be discussed in more detail in later sections. 
Obesity-related hypertension 
Hypertension is the most common co-morbidity associated with obesity (29). 
Thirty-six percent of overweight (BMI >25) individuals are hypertensive and over sixty 
percent of obese (BMI >35) individuals are hypertensive (30). 
Researchers have found a close correlation between increased BMI and increased 
rates of hypertension (2,25,31). The prevalence of hypertension in overweight 
individuals is 2.9 times higher than in non-overweight individuals ( 10). When an 
individual is diagnosed with hypertension, one of the first recommendations is 
maintaining a healthy weight, or weight reduction if the individual is overweight 
(24,25,32,33). 
Adipose tissue physiology 
Adipose tissue is a specialized form of loose connective tissue containing 
undifferentiated fibroblasts (preadipocytes ), adipocytes, vascular and endothelial cells 
(5,34). Fat is stored in the form of triglycerides in the adipocytes. Adipose tissue pads 
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and protects organs, insulates the body and stores energy in the form of triglycerides for 
use in times of metabolic need (6,10,35). Adipose tissue mass can be increased in two 
ways, either by hypertrophy, expanding the size of the adipocyte by storing more 
triglycerides, or by hyperplasia, increasing the number of adipocytes (36). 
Adipose tissue plays a more complex role in whole body homeostasis than just 
energy regulation. Recent research shows that adipose tissue is not only a storage site for 
excess energy, but also an endocrine, paracrine/autocrine organ (6,35). 
Distribution of fat depots is also an important indicator of disease risk. Different 
depots of tissue vary in their level of metabolic activity and metabolic risks (4). Upper­
body obesity, known as android obesity, is associated with increased rates of heart 
disease, hypertension and type 2 diabetes ( 4 ). Excess abdominal fat has a stronger 
correlation with coronary heart disease than does thigh or gluteal fat pads (36). 
Individuals with lower-body obesity, gynoid obesity, usually have a lower health risks, 
however it is often harder to lose this weight (4). These differences could be due to the 
composition, amount of blood flow and the metabolic role of each tissue depot, as well as 
differences in response to nutritional and hormonal stimuli (4). 
Renin-Angiotensin System (RAS) 
Systemic RAS 
The Renin-Angiotensin System (RAS) is comprised of two enzymatic reactions 
that convert angiotensinogen (agt) into angiotensin II (ang II) (Figure 1) (7). Agt is the 
only precursor for ang II. RAS is one of the main regulators of blood pressure, plasma 
volume, sympathetic nervous activity and thirst responses (37). The end product, ang II 
is a vasoactive hormone that is able to act systemically as well as locally. 
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Agt is a glycoprotein synthesized by the liver. The liver only stores small 
quantities; therefore it is made and released as needed. Renin is a protease synthesized 
and stored by the juxtaglomerular apparatus in the afferent arterole of the kidney. Renin 
cleaves agt into angiotensin I (ang I), an inactive intermediate in the pathway. 
Angiotensin Converting Enzyme (ACE) is a dipeptidyl peptidase that cleaves the 
carboxyl-terminal end of ang I and forms the active octapeptide, ang II. There are several 
other enzymes that are able to convert agt to ang II (tissue plasminogen activator, 
cathepsin G, tonin) and ang I to ang II (chymostatin-sensitive angiotensin II-generating 
enzyme, cathepsin G, chymase) (38). The clinical significance of these alternate 
pathways is unknown. 
Decreased blood pressure and sodium concentration stimulates renin release and 
increases ang II production (7). Ang II effects are mediated by specific receptors 
throughout the body and uses different signaling mechanisms (39). 
RAS-related hypertension 
The association between obesity and hypertension has been established for a long 
time, but the mechanisms behind this relationship are not completely understood ( 40). 
The RAS pathway is a major determinant in hypertension. 
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Ang I I  increases sodium concentration, blood volume and blood pressure. This is 
accomplished by the actions of different signaling mechanisms (Figure 1) and at several 
sites in the body. 
In the kidney, ang I I  contracts glomular mesangial cells and smooth muscle in the 
efferent arterioles of the kidney to decrease filtration (4 1). In the pituitary, ang II 
increases the secretion of vasopressin, which is a vasoconstrictor and anti-diuretic ( 4 1  ). 
In the brain, ang II increases salt appetite and thirst ( 4 1  ). Ang II increases heart rate, 
constricting blood vessels and smooth muscle cells ( 4 1  ). Ang II acts on the glomerulosa 
cells of the adrenal cortex that release aldosterone and signal the reabsorption of sodium 
and water in the kidneys ( 4 1  ). The net effect of all of these actions is increased blood 
pressure. 
Angiotensinogen ( agt) 
i _________ Renin 
Angiotensin I (Ang I) 
I �-------- Angiotensin Converting 
+ Enzyme (ACE) 
Angiotensin II (Ang II) 
.-----------I �-------. aldosterone 






i blood pressure 
Figure 1. RAS and its biological effects. 
1 1  
Two of the commonly prescribed blood pressure medications function by 
blocking the RA S. One inhibits A CE and blocks the conversion of ang I to ang II. The 
other blocks an ang II receptor, preventing ang II from acting on target cells. Treatment 
with both A CE inhibitors (such as captopril) and AT 1 receptor antagonists (such as 
losartan) have been clinically shown to significantly reduce blood pressure ( 4 2-46). 
Ang II Receptors 
Ang II acts through two main receptors: angiotensin II type 1 (AT 1) and type 2 
(AT 2) receptors. Although several others have been reported, they are less studied 
(3 9,47). Both receptors are G-protein coupled and have seven hydrophobic 
transmembrane segments (3 7). The receptors have unique signaling and physiological 
functions as well as different sites of expression (37,48). There is a 3 4  percent homology 
between the amino acid sequences of the two receptors (4 9,50). The receptors are able to 
be distinguished from each other according to their inhibition by specific receptor 
antagonists (Figure 2). A T  I receptors are selectively blocked by biphenylimidazoles such 
as losartan, and AT  2 receptors are blocked by tetrahydroimidazopyridines such as PD 
1 23,3 1 9  (PD), also called P- 186 (5 1- 5 4). 
The A T  I receptor is expressed in somatic and brain tissues, and located primarily 
in the adrenal glands, vascular smooth muscle cells, kidney and heart (5 2). The 
biological actions of ang II discussed earlier such as vasoconstriction, aldosterone 
secretion, osmoregulation and sodium balance are mediated though the AT  I receptor 
(37,47,52,5 4,5 5). 
1 2  
agt 
i-◄---remn 








Figure 2. Antagonism of RAS. 
The AT 1 receptor has two isoforms in the rat, AT IA and AT  IB, which share 94% 
homology (56,57). The ATIA isoform is found predominantly in the kidney, liver, lung 
and vascular smooth muscle, whereas the AT 18 isoform is found predominantly in 
adrenal and anterior pituitary glands (5 4). Through selective receptor inactivation in 
knockout mice, researchers have determined that the AT  IA receptor is responsible for the 
systemic blood pressure effects of ang II (58-60). 
Ang II binding at AT 1 receptors in blood vessels causes vasoconstriction and 
increases blood pressure (6 1,62). In addition, the AT I receptor mediates the growth and 
proliferation of cardiac myocytes, causing cardiac hypertrophy independent of blood 
pressure (5 4). All of these effects contribute to the pathology of hypertension. 
13 
The AT 1 receptor has 5 different signaling mechanisms: activation of 
phospholipase A2 (PLA2) ,  phospholipase C (PLC), phospholipase D (PLD), L-type 
calcium (Ca2+) channels and inhibition of adenylate cyclase (AC) (reviewed in (54)). 
Activation of PLC results in the formation of inositol 1,4,5 triphosphate (IP3) and 
diacylglycerol (DAG) from phosphatidylinositol 4,5-bisphosphate (PIP2) .  IP3 increases 
intracellular Ca2+ and DAG activates protein kinase C (PKC), with the final effect of both 
being vasoconstriction. The inhibition of AC also causes vasoconstriction by decreasing 
levels of adenosine 3 ',5 '-monophosphate ( cAMP), a vasodilator. Opening Ca2+ channels 
also signals vasoconstriction and aldosterone production and release. The activation of 
PLA2 releases arachidonic acid, which produces prostaglandins. 
Until recently there was little known about the AT 2 receptor. It was originally 
distinguished from the AT 1 subtype by its resistance to sulfhydryl-reducing agents and 
GTP and the inhibition of T-type (cytosolic) Ca2+ channel currents (63-65). Unlike AT 1 , 
which is associated with many tissues, the AT 2 receptor is predominantly found in fetal 
tissues, developing brain, adrenal glands and ovarian follicles ( 49,64,66,67). The 
expression of the AT 2 receptor in these tissues suggests a role in growth and 
development. The AT 2 receptor is expressed almost exclusively in fetal tissues, but then 
declines dramatically after birth (68,69). Expression of the AT2 receptor is upregulated 
during times of injury, such as wound healing and vascular remodeling (52). 
In general, the cardiovascular effects of the AT 2 receptor seem to be functionally 
opposite to those of AT 1 (70). For example, AT 2 receptor knockout mice exhibit 
increased blood pressure. A possible explanation is that the AT 2 receptor regulates 
1 4  
Table 4. Summary of the main fun ctions of AT 1 and AT 2 receptors. 
AT 1 
somati c and brain tissues 
fluid-ele ctrolyte balance 
blood pressure regulation 
vasoconstri ction 
aldosterone synthesis and se cretion 
renal sodium reabsorption 
vasopressin secretion 
cardia c hypertrophy and contractility 
AT2  
fetal tissue development 
cell proliferation 
cell differentiaion and development 





vasodilation (7 1, 7 2). However, when the AT  1 re ceptor is blocked, the AT 2 receptor is 
able to regulate vasoconstri ction (3 7 ). Table 4 is a summary of the main fun ctions of the 
AT 1 and AT2 re ceptors (37,5 2,54,73,7 4 )  
The AT2 receptor is G-protein coupled, however it does not appear to function by 
the typical signaling pathway (3 9 ). Ang II binding at the AT  2 re ceptor inhibits guanylate 
cyclase (GC )  a ctivity (7 5 ). This de crease in GC  causes an AT  2 -mediated decrease in 
cGM P  levels ( 6 5 ). 
Adipose Tissue RAS 
In addition to the classi cal system des cribed earlier, there are several peripheral 
tissues that contain their own local RA S (76 ). Adipose tissue is one of these tissues, 
having all of the components ne cessary to produce ang II lo cally (77, 78). The products of 
adipose tissue RA S not only act dire ctly on adipose tissue, but also are able to contribute 
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systemically to blood pressure regulation and kidney filtration (78, 79). This suggests that 
this adipose tissue RAS plays an important role in obesity and obesity-related 
hypertension. 
Regulation of RAS 
As the precursor to the RAS pathway, availability of agt is a major regulator of 
the amount of ang II that is produced. Agt is produced in adipose tissue (77, 78,80) and 
contributes to circulating agt levels (81 ). Proportionally elevated levels of agt are seen 
with increased BMI (82,83), implying that agt production is directly related to amount of 
adipose tissue. Adipose tissue is able to indirectly regulate agt circulating levels in part 
through estrogen (81 ). Adipocytes produce estrogen which is able to bind hepatic 
receptors to increase agt expression (81 ). 
Agt mRNA is nutritionally regulated in adipose tissue. Both agt mRNA and 
protein are decreased during fasting and increased with refeeding (80). Ang II, fatty 
acids, adrenal glucocorticoids and insulin increase adipocyte-derived agt (7 ,84-86) Agt 
mRNA is expressed in a differentiation-dependent manner (87). Stimulators of adipocyte 
differentiation as well as lipogenic factors such as isobutylmethylxanthine, 
dexamethasone, ethynylestradiol and T3 also increase agt mRNA levels (87,88). 
Conflicting results have been reported regarding the effects of obesity on agt expression 
(89). Expression of agt mRNA is decreased in obese adult Avy and fatty rats, but 
increased in ob/ob and db/db mice and in young fatty rats (80,86,90). However, further 
1 6  
studies are needed to determine if these differences are possibly due to the developmental 
stage, mutation or sex (89,9 1 ). 
Effects of RAS 
Endocrine effects 
Adipocyte agt contributes to circulating levels of agt (79,80,92) and affects 
systemic RAS functions. Massiera et al. reported increased fat mass and high blood 
pressure in transgenic animals that over-express agt in adipose tissue (79). While 
knockout mice exhibit low blood pressure, decreased adiposity and renal abnormalities, 
re-expressing agt in these mice normalized fat mass as well as restored blood pressure 
and renal functions of these animals (79). Recent studies from our lab confirmed these 
changes in adiposity in the knockout and transgenic versus the control mice (93). This is 
a prime example of the endocrine capacity of adipose tissue, which also establishes a 
direct relationship between adipose tissue mass and hypertensive effects; hence, obesity­
related hypertension. 
Paracrine effects 
In adipose tissue, ang II stimulates adipocyte growth and differentiation (94,95). 
By using receptor antagonists, studies from our lab and others identified the AT 2 receptor 
as the predominant receptor expressed in adipose tissue (94,96). Furthermore, the effects 
of ang II on adipocyte lipogenesis were shown to be mediated by the AT 2 receptor (96). 
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Adipose tissue hyperplasia is regulated by ang I I  in a paracrine manner: ang I I  
stimulates the release of prostacyclin (PG I 2) by mature adipocytes (94,97). The P G h  
produced stimulates the differentiation of preadipocytes into adipocytes in ob 1 77 1 cells 
(Figure 3) (94). Administering the AT 2 receptor antagonist blocked both the production 
and lipogenic effects of P G h  demonstrating that both of these actions are mediated by the 
AT 2 receptor (94). 
Hypertrophic growth of the adipocyte is also regulated via the AT 2 receptor. The 
acti vities of both fatty acid synthase (F A S) and glycerol-3-phosphate dehydrogenase 
(G PD H) are increased when ang I I  binds at the AT 2 receptor (96). The net effect of 
increasing these enzyme activities is triglyceride synthesis (Figure 3). Inhibition of the 
A T  2 receptor by PD prevents these effects (96). 
pr eadipo cyt e  
d iffe re n t ia t i on  




i tr i gl yc er id e s  
i l ip o gen e s i s  
i F A S  a n d  G P D H 
i A G T  
i l ept i n  
Figure 3 .  Summary of ang I I  effects in adipose tissue via the AT 2 receptor. 
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In tissues that express both AT 1 and AT 2 receptors, the AT 2 receptor h as the 
ability to function as an ant agonist by b inding directly to the AT 1 receptor and inh ibiting 
its activation (98). 
Un fortunately the d at a  on ang II receptors in adipose tissue is still sp arse and 
sometimes controversial. This is possibly due to vari ance in receptor express ion and 
activity depending on species, development al st age and nutrition al and hormonal st ates. 
T able 5 is an overview of results thus far. 
In summary, adipose tissue produces ang II as well as other lipogenic factors, 
which in tum incre ase the amount of adipose tissue through both hypertrophy and 
hyperpl asia. This is a vicious circle that ultim ately le ads to high blood pressure (Figure 
4). Adipose tissue affects blood pressure via adipose tissue derived agt (A T 1 signaling) 
th at enters the bloodstre am (7 9) and also via the p aracrine effects of ang II (AT 2 
s ign aling). 
Figure 4. Summary of endocrine and par acrine effects of adipose tissue 
on blood pressure. 
1 9  
Table 5 .  Current research on ang II receptor expression in adipose tissue. 
receptor animal location of type of adipose preadipocyte 
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DIFFERENTIAL EFFECTS OF ANGIOTENSIN II TYPE 2 RECEPTOR 
ANTAGONISM ON ADIPOSITY IN MICE MODELS OF OBESITY 
Introduction 
With the discovery of a local RAS in adipose tissue, the importance of 
understanding ang II effects becomes crucial in researching obesity-related hypertension 
and other disorders. It is now well established that ang II increases adipocyte 
differentiation (94) and lipogenic enzymes (96) in adipocytes and that this occurs via the 
AT 2 receptor. However, these findings have all been performed using in vitro studies. 
The purpose of this research is to test these effects in vivo. 
Preliminary studies from our lab explored the effects of ang II receptor 
antagonists in lean, normal C57BL/6J mice (106). The animals lost weight and had 
smaller fat pad weight and lower leptin levels when treated with AT 2 antagonist PD vs. 
vehicle. This experiment was repeated in a db/db obese mouse, to test the weight 
reducing effect of PD in a genetically obese mice (106,107). Surprisingly, AT2 
antagonism in these animals increased body weight and leptin levels. Both of these 
studies were confirmed by primary culture of adipocytes from these mice where 
treatment with the AT 2 antagonist in adipocytes from lean mice reduced leptin secretion 
2 1  
compared to vehicle and ang II treatment (106, 107). Treatment with the AT 2 antagonist 
did not have an effect in the db/db mice (106,107). The db/db mice have severe diabetes, 
kidney disease and obesity, which may have played a role in these unexpected results. In 
addition, the db/db mouse is on a different genetic background than C57BL/6J, which 
may be an additional confounding variable. 
Research Objectives 
Given the above-described studies from our lab, and the conflicting effect of PD 
in lean vs. obese db/db mice, the goal of this thesis project was to further investigate the 
effects of AT 2 receptor antagonist in other mouse models of obesity. Specifically, we 
propose the following aims: 
1. Determine the effects of the ang II receptor antagonist in another genetic model of 
obesity, the leptin deficient ob/ob mice. The antagonist was administered in vivo to 
these mice or used to treat primary adipocytes isolated from these animals. Due to 
limited availability of ob/ob mice, PD was the only drug used in this study. 
2. Determine the effects of ang II antagonism in a non-genetic model of obesity, high-fat 
diet induced obesity (DIO). This model more closely mimics human obesity. After 
obesity is induced, mice are treated with the antagonist and switched to a chow diet 
(DIOI )  or kept on a high-fat diet (DIO2). In addition, adipocytes from these obese 
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mice were cultured in vitro to inve stigate the dire ct effe ct of the antagoni st. In 
addition to the AT 2 antagoni st, the AT 1 antagoni st , losartan, and A CE inhibitor, 
captopril were u sed in all DIO experiment s a s  additional mean s to block the action or 
production of ang II. 
Experimental Design and Approach 
Animals 
Twenty- four 6-week-old male ob/ob mice (C 57BL/6 J  background) were 
purchased from Jack son Lab s (Bar Harbor, ME). The animal s were maintained on a 
chow diet throughout the experiment . A fter a one-week acclimation period, mi ce were 
divided into two group s, control (n= 1 2) and treatment (n= 1 2) group. The control group 
wa s injected with phosphate buffered saline (PB S). The treatment group wa s inje cted 
with PD 1 23,3 1 9  ditrifluoroa cetate (PD) (Si gma, St. Loui s, M O) ( 1 5  mg/kg body weight) 
di ssolved in PB S. The animal s were given subcutaneou s injection s daily for 2 1  day s and 
were sacrifi ced on day 22. 
DIO I :  Treatment of chow -fed mice 
Twenty-nine 6 -week-old ma le C5 7BL/6J mice we re purcha sed from Jack son Labs 
(Bar Harbor, ME). The animal s were fed a high fat diet (4 5 k cal% fat) (D 1 24 5 1 ,  
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Research D iets, New Brunswick, NJ) for 10 w eeks to induce obes ity (See append ix A-2 
for d iet compos it ion). At th e start of inj ect ions, the an imals were  sw itch ed to chow d iet. 
Th e an imals w er e  d iv id ed into four groups: control (n=7), AT 1 antagon ist (n=7), 
AT  2 antagon ist (n =8) and A CE inhib itor (n =7). The control group was inj ect ed w ith 
PB S. The AT  1 antagon ist group was inj ect ed w ith losartan (Merck, Wh it ehouse Stat ion, 
NJ) ( 1 5 mg/kg body w eight). Th e AT 2 antagon ist group was inj ect ed w ith PD ( 1 5 mg/kg 
body w eight). Th e A CE inh ib itor group was inj ect ed w ith captopr il (S igma, St. Lou is, 
M O) (0.6 25 mg/kg body w eight). All drugs w er e  d issolved in PB S. Th e an imals w ere  
g iven subcutan eous inj ect ions da ily for 1 9  days and w ere  sacr ific ed on day 20. 
DIO2: Treatment of h igh -fat-fed mice 
Forty 6 -w eek -old C 57BL/6J  mice w er e  purchas ed from Jackson Labs (Bar 
Harbor, ME). Th e an imals w er e  fed a h igh fat d iet (4 5 kcal% fat) (D 1 24 5 1, R esearch 
D iets, New Brunsw ick, NJ) for 1 2  weeks to induce obes ity (See append ix A-2 for d iet 
compos it ion). Th e an imals r emained on the h igh-fat d iet throughout the cours e of the 
exper iment. 
The an imals w er e  d iv ided into four groups: control (n= 10), AT  1 antagon ist 
(n = 10), AT  2 antagon ist (n = 10) and A CE inhib itor (n= 10). Th e dosage of losartan for th e 
AT  1 antagon ist group was increas ed to 30 mg/kg body w eight. Th e dosage of PD for the 
AT  2 antagon ist group was also increas ed to 30 mg/kg body w eight. 
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The dosage of captopr il for the ACE inh ib itor group was increased to 1.25 m g/kg 
body we ight. The drugs were d issolved in PB S and were g iven da ily by subcutaneous 
inject ion. 
Due to the large number of an imals, half the an imals in each group were 
sacr ificed a fter 2 1  days of treatment and the other half after 22 days. The an imals 
sacr ificed on day 2 1  were injected for 20 days and the an imals sacr ificed on day 22 were 
injected for 2 1  days. 
An overv iew of the exper imental des ign can be found in F igure 5. 
A dose response in lean and DIO m ice is ideal to determine the most effect ive 
dose of PD. The dose chosen here took into the account the cost and ava ilab il ity of PD, 
and the prev ious find ings from our lab and others ( 106 - 1 10). 
Based on publ ished stud ies, the doses of both losartan and PD used in rodents 
range from 5 to 50 mg/kg body we ight ( 108- 1 10). The dosages were chosen to be w ith in 
th is range and were based on prev ious find ings from our lab us ing lean m ice where 1 5  
mg/kg body we ight was su ffic ient to not ice s ign ificant decrease in body we ight and lept in 
( 106, 107). 
The prescr ibed dose of captopr il for humans is 25 to 50 mg/day ( 1 1 1). Based on a 
70 kg person, th is is 0.3 57 to 0.7 1 4 mg/kg body we ight. The lower dosage of captopr il 
used in the DI O 1 s tudy (0.6 25 mg/kg body we ight) is w ith in th is range and comparable to 
what is prescr ibed. The DIO2 dosage ( 1.25 mg/kg body weig ht) is above the norma l 
range prescr ibed. 
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Figure 5. Overview of experimental design of animals studies. The animals were fed chCMt diet unless 
otherwise specified. DIO
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In all of the above studies the animals were given free access to food and water. 
The environment was temperature controlled and on a 1 2  hour light /dark cycle. 
The animals were randomized into groups such that the average weight in each group was 
comparable. The animals were weighed twice a week and the amounts injected were 
recalculated accordingly. The food was weighed daily . In cases when there were two or 
more animals per cage, the food weight was averaged for each animal. Unless specified, 
the animals were maintained on chow diet (86 40, Harlan, Madison, WI) (See appendix 
A- 1 for diet composition). 
All animals were fasted for 10 hours pr ior to sacr ifice . On the day of sacr ifice, 
the animals were exsanguinated while under iso fluorine anesthesia. Blood was collected 
by cardiac puncture. The following tissues were harvested: liver, kidney, epid idymal fat 
pad, abdominal fat (perirenal and mesenteric fat pads), heart and brain. The liver and 
adipose tissue samples were weighed at the time of collection. All tissues were snap 
frozen in liquid nitrogen for further analysis. 
Primary culture of adipocytes 
D1 0 mice were sacrificed by the aforementioned procedure. Pr imary culture of 
adipocytes was performed as previously described ( 1 1 2). The adipose tissue was 
removed and washed twice with Hanks . The tissue was cut into small pieces and divided 
into culture dishes ( 100 mm or 3 5mm/6 well plates). The tissue was incubated with 
DM EM media supp lemented with 1 % B SA, 0. 1 % FB S, 1 % penicillin /s treptomyc in and 
0.5% gentamicin for 48 hours. The med ia was remov ed after 2 days and r epla ced with 
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new media containing the following treatments: PB S, ang II ( l0nM), PD ( l00 µM) and 
both ang II and PD. A fter two days of incubation, the media was removed and frozen. 
When applicable, fresh media along with the treatment was added and incubated another 
day be fore both tissue and media were collected. The doses of ang II and PD used were 
submaximal and were based on previous dose-response studies in our lab. 
Glucose 
Fasting blood glucose readings were taken at the time of sacrifice. The whole 
blood was measured using a ONE TOUCH Profile glucose meter (Life Scan, Milpitas, CA). 
Leptin and Insulin Radioimmunoassay 
Leptin and insulin concentrations were determined by radioimmunoassay (RIA). 
The leptin was measured using a mouse leptin RIA kit from Linco Research (St. Charles, 
MO). The leptin concentration was measured using 50 µL of plasma for both DI O in 
vivo studies and 100 µL of media from the in vitro studies. The insulin was measured 
usin g a rat insulin RIA kit from Linco Research (St. Char les, M O). Insu lin 
concentrations were measured using 50 µL of plasma from both of the DIO in vivo 
studies. 
RIA kits measure hormone concentrations by quantifying the amount of binding 
to a specific antibody. This is done by allowing the hormone and antibody to bind, and 
then introducing a radiolabeled hormone. In this case the proteins were labeled with 1 251. 
The radio-labeled hormone will bind to open sites on the antibody where the samp le has 
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not bound. The rad ioact iv ity is measured on a gamma counter and there is an inverse 
relat ionsh ip between the amount of rad ioact iv ity present (in counts per m inute) and 
hormone concentrat ion. Th is relat ionsh ip is graphed form ing a standard curve us ing 
standard concentrat ions prov ided w ith the k it. The sample values are extrapolated based 
on th is standard curve. 
FAS and GPDH assays 
The ep id idymal fat pads were homogen ized in 250 mM sucrose buffer conta in ing 
protease inh ib itor, 0. 1 mM phenylmethanesulfonyl-fluoride (PM SF) and centr ifuged to 
collect the cytosol ic fract ion. The act iv it ies of F A S  and G PDH were determ ined in 
cytosol ic extracts by measur ing the rate of oxidat ion of NADPH (for FAS assay) and 
NADH (for GPDH assay) ( 1 13). The ox idat ion rate was measured 
spectrophotometr ically at 3 40nm. These numbers were corrected for prote in 
concentrat ion. 
Protein assay 
Prote in concentrat ion was determined by the Brad ford assay ( 1 1 4). The dye used 
for th is assay, Coomass ie blue (Bio-Rad), is a red-brown that absorbs l ight at 470nm. 
When the dye b inds to prote in, the color changes to blue and the absorpt ion wavelen gth 
sh ifts to 5 9 5nm. 
Each sample was done in dupl icate w ith 10 µL sample and 200 µL of dye be in g  
comb ined in a 96 -well plate . After a 5 minute incubat ion, the plate was read at 5 90nm. 
A standard curve was created using dilutions of bovine serum albumin (B SA) at known 




RNA was extracted from abdominal fat pads by homogenizing adipose tissue in 
guanidine isothiocyanate (G T C) (lnvitrogen, Carlsbad, CA) containing 7% �­
mercaptoethanol and purified using the cesium chloride density gradient method ( 1 1 5). 
The RNA was further purified using phenol/chloro form (Ambion, Austin, TX) followed 
by ethanol precipitation. RNA was resuspended in 0. 1 T E  and stored at -80 °C until 
further analysis. 
Real time PCR 
Expression of F A S  m RNA was determined using real time P C R  ( 1 16). This 
probe-based P C R  product detection was used to quantify RNA concentration from a 
standard curve that was obtained using total RNA. 
Real time P C R  was used because it is more sensitive that a Northern blot and can 
quickly and accurately quantify concentrations of RNA. During the P C R  reaction, the 
probe binds specifically to the target sequence. The probe has a fluorescent reporter dye 
and quencher dye that, when in close proximity, reduces the fluorescence of the reporter. 
The probe is cleaved by Taq polymerase at the 5 '  end when the primer is extended. This 
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cleavage separates the reporter from the quencher, which increases the signal of the 
reporter. 
The primers and probe were ordered from Sigma Genosys (The Woodlands, TX). 
The sequence of the forward primer is 5' CCCAGAGGCTTGTGCTGACT 3'. The 
sequence of the reverse primer is 5' CGAATGTGCTTGGCTTGGT 3' . The sequence of 
the probe is 5' (TET)CCGA TCTGGAA TCCGCACCGG(T AMRA) 3 '. The SmartCycler 
software (Cepheid, Sunnyvale, CA) was programmed as indicated in Table 6. 
Statistical analysis 
Statistical analysis was done in SPSS (SPSS for Windows, Rel. 11.0.1.2001. 
Chicago: SPSS Inc.) The data was analyzed using either a one-way analysis of variance 
(ANOVA) or t-test. Tukey's HSD post-hoc analysis was used to determine differences 
between groups if the ANOV A was significant ( 117). A 95% confidence interval was 
used in determining significance in all tests. All data is expressed as mean ± SD. 
Table 6. Cycles of real time PCR. 
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Effects of ang II antagonism in ob/ob mice 
Treatment with PD lowered abdominal fat pad weights (p<0.001) and decreased 
FAS activity (p<0.03) in ob/ob mice (Figure 6). There was no difference in FAS mRNA 
concentration with treatment of PD. It is worth noting that gene expression was 
measured in epididymal fat pads, which was not responsive to PD. There was no change 
in body weight at the end of treatment, amount of weight gained over the course of 
treatment, food intake per day, blood glucose, epididymal fat pad weight or GPDH 
activity in PD-treated mice vs. control (Table 7 and Figure 7). 
Effects of ang II antagonism in DIO 1 mice maintained on chow diet 
Treatment with PD decreased blood glucose levels in the DIOl mice compared to 
control mice (p<0.03) (Table 8). Captopril also decreased blood glucose but this effect 
did not reach significance (p=0.075). In addition, at the end of treatment, there was no 
difference in body weight, amount of weight lost over the course of treatment, food 
intake per day, fat pad weights, leptin levels, insulin levels, FAS or GPDH activity 
between PD and vehicle groups (Figure 8). 
Effects of ang II antagonism in D/02 mice maintained on high-fat diet 
DIO2 mice treated with PD lost more weight over the entire treatment period than 
all other groups (p<0.01) (Figure 9). Food intake was higher in mice treated with 
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Tabl e  7 .  Eff ects of an g II antagonism in ob/ob mice. 
control P D  
(n= l 2) (n= l 2) 
body w eight (g) at the end of 
tr eatment 5 5. 1  ± 2.8 5 5.5 ± 2.7 
w eight gain  (g) over cours e of 4. 1 ± I. I 3.6 ± 1.2 treatment 
food intake/day (g) 5.8 ± 0.4 5.9 ± 0.3 
blood glucose (m g/dL) 266 ± 6 9  266 ± 6 1  
epididymal fat pad (g) 4.5 ± 0.6 4.2 ± 0.4 
GPDH activity (nmol 
NAD H/min/m g  protein) m easur ed 4.5 2 ± 2.64 5.38 ± 1.08 
in epididymal fat pad 
FA S mRNA concentrat ion (n g/µL) 1 4.98 ± 1.0 9  18. 1 9  ± 1.0 4 measured in abdominal fat pad 
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Figure 6. Effects of AT2 receptor antagonism on abdominal fat pad weight and F A S  
activity in ob/ob mice. 
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Figure 7. Change in body w eight of ob/ob mic e over cours e of treatment. 
Table 8. Effects of a ng II anta gonists in DIO I mice. 
control losartan PD captopril 
(n=7) (n=7) (n =8) (n=7) 
body wei ght (g) at the 3 1.7 ± 2.0 3 1 .5 ± 2.1 3 2.4 ± 2. 1 3 1.8 ± 2.0 end of treatment 
wei ght loss (g) over the 3.0 ± 1.7 3.0 ± 2.2 2.7 ± 2. 1 3. 1 ± 1.8 course of treatment 
food intake /day (g) 4.3 ± 0.5 4.4 ± 0 .5 4.5 ± 0.6 4.6 ± 0.5 
blood glucose (mg/dL) 20 5 ± 28b 186 ± 1 1 6a,b 1 67 ± 23 a 173 ± 26 a,b 
epididymal fat pad (g) 0 .8 ± 0.3 0.7 ± 0.4 0.8 ± 0 .3 0.8 ± 0.3 
abdominal fat pad (g) 0.7 ± 0.4 0.6 ± 0.3 0.7 ± 0.3 0.6 ± 0.3 
leptin (n g/mL) 4.9 1 ± 2.0 5 3.27 ± 0.66 5.37 ± 2.03 3.9 1 ± 1.3 2  
insulin ( ng/mL) 0.90 ± 0.5 2  0.66 ± 0. 1 9  0.8 1 ± 0.3 4 0.58 ± 0.2 1 
F A S  activity (nmol 
NADPH/min /m g  2.0 6 ± 0.87 1.29 ± 0.70 1.27 ± 0.85 1.30 ± 0.5 5  protein) measured in 
epididymal fat pad 
GPD H  activity (nmol 
NA D H/min/m g  protein ) 3.60 ± 0.7 5  5.27 ± 4.0 4 3.0 2 ± 1.4 5 3.63 ± 1. 1 5  measured in epididymal 
fat pad 
Values with the different letters are si gnificantly different (p<0.0 5 ). Values with the 
same letter are not significantly different. 
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* 
2 1  or 22 
F igure 9. Change in body we ight ofDIO2  mice over course of treatment. *Mice injected 
w ith PD lost more we ight than veh icle-treated mice (p<0.03 at day 1 1, p< 0.00 2 at day 
1 5, p<0.0 1 at day 18 and 2 1 /22). 
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losartan vs. PD (p<0.0 1), and was also higher in losartan (approached significance, 
p =0.0 56) compared to vehicle-treated mice (Figure 10). At the end of treatment, there 
was no difference in body weight, blood glucose, fat pad weights, leptin, insulin, F A S  or 
G PD H  activity between any of the groups of mice (Table 9). 
Effects of ang II and PD in primary ad ipocytes 
When primary adipocytes from DI O mice were treated with ang II there was no 
change in leptin secretion (Table 10). There was also no effect with PD treatment alone 
or with ang II and PD in combination. 
Discussion 
Our lab has previously shown that blocking the A T  2 receptor decreases fatty acid 
and triglyceride synthesis in cultured 3 T3-Ll adipocytes (96). In addition, Darimont et 
al. demonstrated that the AT 2 receptor mediated ang II-induced P G b  release and 
adipocyte differentiation in cultured ob 177 1 adipocytes (94). In agreement with these 
findings, pilot studies from our lab demonstrated that the AT  2 receptor antagonist, 
PD 1 23,3 1 9, decreased weight gain, fat pad weight and plasma leptin in lean C 57 BL/6 J  
mice, while in db/db mice, PD increased we ight gain and pla sma leptin leve ls ( 106, 107). 
The observations indicate that the AT  2 r eceptor mediat es ang II effects on adipose tissue 
metabolism. 
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Table 9 .  Effects of ang II antagonism in DIO2  mice . 
control losartan PD captopril 
(n=l 0) (n =l0) (n = I O) (n =l O) 
blood glucose (mg/dL) 1 92 ± 54  225 ± 3 5  203 ± 37 1 9 9  ± 3 5  
epidid ymal fat pad (g) 1. 1 ± 0.5 0 .9 ± 0.4 0.8 ± 0 .4 1.2 ± 0.7 
abdominal fat pad (g) 0.9 ± 0.4 0 .5 ± 0.3 0.6 ± 0.4 0.9 ± 0.6 
leptin (ng/mL) 8.28 ± 5.7 2 4.36 ± 2. 1 5  5 .76 ± 4.88 9.38 ± 7 . 1 4  
insulin (ng /mL) 0 .6 5  ± 0.80 1.00 ± 1. 17 0.60 ± 0.7 5  0.6 1 ± 0.36 
FAS  activity (nmol 
NAD P H/min/mg protein) 2. 1 4  ± 0.63 2.0 1 ± 0.80 1.85 ± 0.66 2.3 1 ± 0.9 1 measured in epidid ymal 
fat pad 
GPD H  activity (nmol 
NADH/min/mg protein) 3.74  ± 1.84 2.64 ± 1.64  2.4 2 ± 1 .82 2.0 2 ± 1.47 measured in epidid ymal 
fat pad 
Table 10 . Effects ofang II and PD on leptin secreted from adipocytes ofDI O mice. 
control ang II PD ang II + PD 
leptin ( ng/mL) 5.6 5  ± 3.7 2  5 .4 4  ± 3 .4 5  4.60 ± 2.84 5.83 ± 3.54 
40 
1 2 3 4 5 6 7 8 9 1 0  1 1  1 2  1 3  1 4  1 5  1 6 1 7  
day of treatment 
--t-control -a-1osartan PD -++-captopril 
Figur e I 0. Effects of ang I I  antagonists on food intake in D1 02 mice. 
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In this study, consistent with findings from Jones et al (96) in cultured adipocytes, 
we found that FAS activity in epididymal fat pad decreased with PD treatment in ob/ob 
mice, however, fat pad weight was unaffected. Gene expression was quantified using 
mRNA isolated from the abdominal fat pads, which were smaller with PD treatment; 
however, FAS mRNA content in this tissue was not affected by PD. The entire 
epididymal fat pad was used for enzyme activity assays; therefore we were unable to 
measure gene expression to determine if the decrease in activity correlates with change in 
FAS mRNA concentration. 
The decrease in blood glucose with PD treatment in the DIOl study is supported 
by recent studies demonstrating increased insulin sensitivity and decreased 
hyperinsulinemia with ang II antagonism ( 118-120). However there was no change in 
insulin levels at the time of sacrifice in our mice. Furthermore, there was no change in 
blood glucose or insulin levels in mice from DIO2 study. 
Treatment with PD did not affect weight loss in the DIOl mice, but did cause 
weight loss in the DIO2 mice. This could be due to the increased dosage of PD (30 
mg/kg body weight) in the second study, or possibly the effect of PD was masked in the 
first study by the weight loss associated with changing the high fat diet to the chow diet 
at the start of treatment. In all studies, regardless if the mice were gaining or losing 
weight, the body weight of the mice decreased over the last interval of measurement 
independent of treatment (Figures 7, 8, 9). 
The only obese animals that exhibited a significant reduction in body weight were 
the DIO2 mice maintained on a high fat diet during AT 2 antagonist treatment. In the 
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DIO 2  study, mice treated with losartan a te more, however, the body weight at the end of 
treatment is not different from other groups. This could be due to increased activity in 
these mice as blocking ang II production in agt knockout mice has been shown to 
increase locomotor activity in these mice ( 1 2 1). Although not measured in this study, we 
observed more aggression and activity in all drug -treated animals. In future studies it 
would be more in formative to measure metabolic activity of these mice. 
Several studies have determined that ang II increases leptin secretion in 
adipocytes in culture (93, 106, 107). Previous studies in our lab have reported that 
treatment with PD  decreased leptin secretion below t he control levels in lean mice 
( 106, 107). In the in vitro study performed here, PD  had no effect on leptin secretion 
from adipocytes of DI O mice. The former studies used 3 T3-Ll and human adipocytes 
(93) while in our current studies we used primary culture of mouse adipocytes. 
In part, our findings support the results from the lean mice study in that some 
metabolic parameters were decreased in ob/ob and DI O mice upon treatment with PD; 
however, not all parameters were consistently affected. However, none of the obese 
models in this study have replicated the increase in adiposity and leptin in the db/db mice. 
The background strain of the db/db mouse is C 57BLKS/J and is different from the 
C 57BL/6J  background of the lean, ob/ob and DIO mice. The unexpected effect of PD in 
db/ db mice may be due to the background strain, genetic mutation, diabetes or kidney 
disease in these animals. 
In using antagonists to block RAS, the expected result, based primarily on in vitro 
studies, is decreased fat pad mass via decreased adipocyte metabolism (9 5,96). In 
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addition, insulin secretion would be lowered and thus decrease its effect on agt 
expression (86), further depressing this system. There is some evidence of these actions 
in the in vivo studies. However, there was no overall or consistent effect of ang II 
antagonism in the different models of mice obesity used in this and previous studies by 
our lab. It is possible that statistical significance may have been achieved in more 
parameters if the sample size had been larger for each group. However significant and 
dramatic changes were previously seen in lean mice with only 6 to 8 mice in each group, 
using the lower dosage of the drugs. It is possible that in an obese mouse there is an 
increased variability in the effects of ang II antagonism and possibly requires a larger 
dosage to see an effect. Alternatively, the responsiveness of obese mice may reflect the 
intrinsic properties of the adipocyte, the level of obesity, diabetes, insulin and leptin 
resistance in these models, which may counteract the weight reducing effect of PD. Just 
as many obese mice are resistant to insulin or leptin, it is possible that obese mice are 
resistant to the effects of ang II in adipose tissue. 
Summary and Conclusions 
The goal of these studies was to confirm in vivo the weight reducing effects of 
RAS blockade. The overall results demonstrate that RAS inhibition does decrease some 
symptoms of the metabolic disorder of obesity. We did see a decrease in weight and FAS 
activity in ob/ob mice and weight and blood glucose levels in D10 mice, however the 
results were inconsistent in the different mouse models of obesity and between normally 
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coordinated parameters (such as glucose and insulin). Additional studies are needed to 
con firm the effects of PD  in obese mice . However, our findings in ob/ ob and DIO mice 
are consistent with a potential role of the AT 2 receptor in adipocyte metabolism and 
energy re gulation . 
The inconsistencies in responsiveness in the above metabolic parameters 
measured in lean vs. obese mice demonstrate the complexity and multi-factorial nature of 
the system being studied. Variability among individuals is inherent to an in vivo study 
and metabolic al terations associated with obesity are additional confounding factors. 
The importance of this research is very signi ficant, however, as RAS has many 
links to the metabolic syndrome of obesity and related disorders. This thesis mainly 
focused on blockade of the adipocyte RAS and the potential of improving both obesity 
and hypertension, which are closely linked. 
In conclusion, blocking ang II reduces hypertension in two ways (figure 1 1) :  by 
decreasing systemic effects of RAS and by inhibiting the excess contribution of adipose 
tissue to ang II production. 
In many cases of hypertension where obesity is the cause, these findings 
constitute a preliminary step to develop treatments for obesity-related disorders that more 
speci fically target the AT 2 receptor instead of blocking the entire RAS. This approach 
would reduce the disruption in systemic functions by targeting adipose tissue. This 
would be especially important in cases of obesity without hypertension that did not 
require a systemic blockage of RAS. However, further studies are warranted to ascertain 
the effects of ang II receptors in mice be fore clinical trials can be undertaken. 
systemic/circulation 
Ang il hypertension 
(endocrine) 
obesity 
Figure 1 1 . Contribution of adipocyte ang II to obesity and hypertension. 
Finally, as with any pharmacological treatment of obesity, AT 2 receptor 
antagonism if proven effective in vivo, should be used in conjunction with behavioral 
therapy including diet and physical activity to reduce weight and adiposity. 
45 
46 
LIST OF REFERENCES 
47 
LIST OF REFERENCES 
1. U.S.Department of Health and Human Service s (200 1) The Surgeon General 's 
Call To Action To Prevent and Decrea se Overweight and Obe sity. Public 
Health Service, U.S. Department of Health and Human Service s, Rockville, 
MD. 
2. N HLB I Obe sity Ta sk Force ( 1 9 98) Clinical g uideline s on the identification, 
evaluation, and treatment of overweight and obe sity in adult s. Obe sity 
Re search 6: 5 1  S-20 9 S. 
3. Pi- Sunyer, F. X. (2000) Health implication s of obe sity. In: Obe sity : Pathology 
and Therapy (Lockwood, D. H. & He ffner, T. G., ed s.), pp. 29- 56. Springer, 
Berlin. 
4. Di Girolamo, M., Harp, J ., & Steven s, J. (2000) Obe sity: Definition and 
Epidemiology. In: Obe sity : Pathology and Therapy (Lockwood, D. H. & 
He ffner, T. G., ed s.), pp. 3-28. Springer, Berlin. 
5. Gregoire, F. M. (200 1) Adipocyte differentiation: from fibrobla st s to 
endocrine cell. Exp Biol Med Vol 226: 9 97- 100 2. 
6. Kim, S. & Mou staid Mou ssa, N. (2000) Secretory, endocrine and 
autocrine/paracrine function of the adipocyte. J Nutr 130: 1 S-6 S. 
7. Dzau, V. J. & Pratt, R. E. ( 1 9 9 2) Renin- Ang ioten sin System. In: The Heart 
and Cardiova scular Sy stem (Fozzard, H. A., ed.), pp. 18 17- 184 9. Raven Pre ss, 
New York. 
8. Engeli, S., Negrel, R., & Sharma, A. M. (2000) Physiology and 
pathophy siology of the adipo se ti ssue renin-angioten sin sy stem. Hypertension 
3 5: 1 270- 1 277. 
9. Flegal, M. D., Carroll, R. J., Kuczmar ski, R. J., & John son, C. L. ( 1 9 98) 
Overweight and obe sity in the United State s: prevalence and trends, 1 960-
1 9 9 4. Int J Obe s Relat Metab Di sord 22: 3 9-47. 
10. Health implication s of obe sity ( 1 985) N I H  Con sen s Statement Online 5: 1-7. 
1 1. Chagnon, Y. C., Peru sse, L., & Bouchard, C. (2000) The molecular and 
epidemiological genetic s of obe sity. In : Obe sity: Pathology and Therapy 
(Lockwood, D. H. & He ffner, T. G., ed s.), pp. 57-89. Springer, Berlin. 
1 2. Stunkard, A. J., Harri s, J. R., & Peder sen, N. L. ( 1 9 90) The body ma ss index 
of twin s who have been reared apart. N Engl J Med 3 22: 1 483- 1 487. 
48 
1 3. Hunt , M. S., Katzmarzyk, P. T., Per usse, L., Rice, T., Rao, D. C., & 
Bouchard , C. (200 2) Familial resemblance of 7-year changes in body mass 
and adiposity. Obesity Research 10: 507- 5 17. 
1 4. Katzmarzyk, P. T., Hebebrand, J., & Bouchard, C. (200 2) Spousal 
resemblance in the Canadian population: implications for the obesity 
epidemic. Int J Obes Relat Metab Disord 26: 24 1- 246. 
1 5. Hill, J. 0. & Peters, J. C. ( 1 9 98) Environmental Contributions to the Obesity 
Epidemic. Science 280: 1 37 1- 1 374. 
16. Gunay- Aygun, M., Cassidy, S. B., & Nicholls, R. D. ( 1 9 97) Prader-Willi and 
other syndromes associated with obesity and mental retardation. Behav Genet 
27: 307- 324. 
17. Hamann, A. & Sharma, A. M. (200 2) Genetics of obesity and obesity-related 
hypertension. Sem Nephrol 22: 100- 10 4. 
18. Wharton , R. H. & Loechner, K. J. ( 1 9 96 )  Genetic and clinical advances in 
Prader-Willi Syndrome. Curr Opin Pediatr 8: 6 18-6 24. 
1 9. Cassidy, S. B. ( 1 9 97) Prader- Willi Syndrome. J Med Genet 34: 9 17- 9 23. 
20. Bray, G. A., Dahms, W. T., Swerdloff, R. S., Fiser, R. H., Atkinson, R. L., & 
Carrel, R. E. ( 1 983) The Prader- Willi Syndrome: a study of 40 patients and a 
review of the literature. Medicine (Baltimore) 6 2: 5 9-80. 
2 1. Lonnqvist, F., Nordfors, L., & Schalling, M. ( 1 9 9 9) Leptin and its potential 
role in human obesity. J Intern Med 24 5 :  6 4 3-6 52. 
22. Robinson, S. W., Dinulescu, D. M., & Cone, R. D. (2000) Genetic models of 
obesity and energy balance in the mouse. Annu Rev Genet 34: 687-7 4 5. 
23. Schalling, M., Johansen, J., Nord fors, L., & Lonnqvist, F. ( 1 9 9 9) Genes 
involved in animal models of obesity and anorexia. J Intern Med 24 5: 6 1 3-
6 1 9. 
24. N HLBI (200 1) Lowering blood pressure. Publication no. 0 1- 328 1  National 
Institutes of Health, Washington DC. 
25. N HLBI and National Hi gh Blood Pressure Education Program ( 1 9 97) The 
sixth r eport of th e Joint National Committ ee on pr evention , d et ection, 
evaluation and treatment of high blood pressure. Publication no. 98- 4080 
National Institutes of Health, Washington, DC. 
26. Vasan, R. S., Larson, M. G., Leip, E. P., Evans, J. C., O'Donnell, C. J., 
Kannel, W. B., & Levy, D. (2001) Impact of high-normal blood pressure on 
the risk of cardiovascular disease. New England Journal of Medicine 345 : 
1291-1297. 
27. Ward, R. (1990) Familial aggregation and genetic epidemiology of blood 
pressure. In: Hypertension: Pathophysiology, Diagnosis and Management 
(Laragh JH & Brenner BM, eds.), pp. 81-100. Raven Press, New York. 
28 . Lander, E. S. & Schork, N. J. (1994) Genetic dissection of complex traits. 
Science 265 : 2037-2048. 
29. Sharma, A. M., Engeli, S., & Pischon, T. (2001) New developments in 
mechanisms of obesity-induced hypertension: role of adipose tissue. 
Curr.Hypertens.Rep. 3: 152-156. 
49 
30. Must, A., Spadano, J ., & Coakley, E. H. (1999) The disease burden associated 
with overweight and obesity. JAMA 282: 1523-1529. 
31. Brown, C. D., Higgins, M., Donato, K. A., Rohde, F. C., Garrison, R., 
Obarzanek, E., Ernst, N. D., & Horan, M. (2000) Body mass index and the 
prevalence of hypertension and dyslipidemia. Obesity Research 8 :  605-619. 
32. Mikhail, N., Golub, M. S., & Tuck, M. L. (1999) Obesity and hypertension. 
Prog Cardiovasc Dis 42: 39-58. 
33. World Health Organization-International Society of Hypertension (1999) 
Guidelines for the management of hypertension. J Hypertens 17: 151-183. 
34. Kawada, T., Takahashi, N., & Fushiki, T. (2001) Biochemical and 
physiological characteristics of fat cell. J Nutr Sci Vitaminol 4 7: 1-12. 
3 5 .  Wiecek A, Kokot F, Chudek J ,  & Adamczak M (2002) The adipose tissue-a 
novel endocrine organ of interest to the nephrologist. Nephrol Dial Transplant 
17 : 191-195. 
36. Bjorntorp, P. (2000) Fat metabolism in obesity, with special emphasis on the 
insulin resistance and elevated lipid mobilization in visceral obesity. In: 
Obesity: Pathology and Therapy (Lockwood, D. H. & Heffner, T. G., eds.), 
pp. 121-131. Springer, Berlin. 
37. Berry, C., Touyz, R., Dominiczak, A. F., Webb, R. C., & Johns, D. G. (2001) 
Angiotensin receptors: signaling, vascular pathophysiology, and interactions 
with ceramide. Am.J.Physiol Heart Circ.Physiol 281: H2337-H2365. 
50 
38. Dzau, V. J., S as amur a, H., & Hein, L. ( 1 9 93) Heterogeneity of angiotensin 
synthetic pathw ays and receptor subtypes : physiologic al and pharm acological 
implic ations. J Hypertens 1 1  (suppl) : S 13- S 18. 
3 9. Ru ffolo, R. R. ( 1 9 94) Angiotensin II receptors, vol. 1 C R C  Press, Boc a R aton. 
40. M asuo, K., Mik ami, H., Ogihar a, T., & Tuck, M. L. (200 1) Weight reduction 
and pharmacologic tre atment in obese hypertensives. Am J Hypertens 1 4 : 
530- 538. 
4 1. In agami T., Mizukoshi M, & Guo DF ( 1 9 9 4) Angiotensin II receptor : 
molecular cloning, functions and regulation. (S aavedr a JM & Timmerm ans 
PBMWM, eds.), pp. 1- 1 5. Plenum Press, New York. 
4 2. Hernandez-Hernandez, R., Sosa- Canache, B., Vel asco, M., Arm as -Hernandez, 
M. J., Armas- Padill a, M. C., & C ammar at a, R. (200 2) Angiotensin II receptor 
ant agonists role in arteri al hypertension. J.Hum.Hypertens. 16 Suppl 1 :  S 93-
S 9 9. 
43. M asuo, K., Mikami, H., Ogih ar a, T., & Tuck, M. L. ( 1 9 97) Metabolic effects 
of long -term tre atments with nifedipine -ret ard and c aptopril in young 
hypertensive p atients. Am J Hypertens 10 : 600-6 10. 
4 4. Conlin, P. R. (2000) Angiotensin II Ant agonists in the Tre atment of 
Hypertension : More Similarities Th an Differences. 
J.Clin.Hypertens.(Greenwich.) 2 :  253-257. 
4 5. Elliott, W. J. (2000) Ther apeutic tri als comparing angiotensin converting 
enzyme inhibitors and angiotensin II receptor blockers. Curr.Hypertens.Rep. 
2 :  40 2-4 1 1. 
46. Simpson, K. L. & Mc Clell an, K. J. (2000) Los art an : a review of its use, with 
special focus on elderly p atients. Drugs Aging 16 : 227 -250. 
47. Timmerm ans, P. B., Wong, P. C., Chiu, A. T., Herblin, W. F., Benfield, P., 
Carini, D. J., Lee, R. J., Wexler, R. R., S aye, J. A., & Smith, R. D. ( 1 9 93) 
Angiotensin II receptors and angiotensin II receptor ant agonists. 
Pharm acol.Rev. 4 5 :  20 5- 25 1. 
48. lnagami, T., Yam ano, Y., Guo, D. F., Fur ut a, H., Ohy am a, K., K ambayashi, 
Y., B ardh an, S., T ak ah ashi, K., & lchiki, T. ( 1 9 9 4) Angiotensin II receptors : 
cloning and expression. Braz.J.Med.Biol.Res. 27 : 1733- 1738. 
4 9. Mukoyam a, M., Nak ajima, M., Horiuchi, M., S asamur a, H., Pr att, R. E., & 
Dz au, V. J. ( 1 9 93) Expression cloning of type 2 angiotensin II receptor 
reveals a unique class of seven-transmembrane receptors. J.Biol.Chem. 268: 24539-24542. 
5 1  
50. Inagami, T., lwai, N., Sasaki, K., Yamamo, Y., Bardhan, S., Chaki, S., Guo, D. F., & Furuta, H. ( 1 992) Cloning, expression and regulation of angiotenisn II receptors. J Hypertens 1 0: 7 13-7 16. 
5 1 .  Carey, R. M., Wang, Z. Q., & Siragy, H. M. (2000) Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 35: 1 55- 1 63. 
52. Unger, T. (2002) The role of the renin-angiotensin system in the development of cardiovascular disease. Am.J.Cardiol. 89: 3A-9A. 
53. de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W., & Unger, T. (2000) International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol.Rev. 52: 4 1 5-472. 
54. Dinh, D. T., Frauman, A. G., Johnston, C. I., & Fabiani, M. E. (200 1 )  Angiotensin receptors : distribution, signalling and function. Clin.Sci.(Lond) 1 00: 481 -492. 
55. Timmermans, P. B., Benfield, P., Chiu, A. T., Herblin, W. F., Wong, P. C., & Smith, R. D. ( 1 992) Angiotensin II receptors and functional correlates. Am.J.Hypertens. 5: 221 S-235S. 
56. Sasamura, H., Hein, L., Krieger, J. E., Pratt, R. E., Kobilka, B. K., & Dzau, V. J. ( 1 992) Cloning, characterization, and expression of two angiotensin receptor {AT-I ) isoforms from the mouse genome. Biochem.Biophys.Res.Commun. 1 85: 253-259. 
57. lwai, N. & Inagami, T. ( 1 992) Identification of two subtypes in the rat type I angiotensin II receptor. FEBS Lett. 298: 257-260. 
58. Ito, M., Oliverio, M. I., Mannon, P. J., Best, C. F., Maeda, N., Smithies, 0., & Coffman, T. M. ( 1 995) Regulation of blood pressure by the type I A  angiotensin II receptor gene. Proc Natl Acad Sci USA 92: 3521 -3525. 
59. Chen, X., Li, W., Yoshida, H., Tsuchida, S., Nishimura, H., Takemoto, F., Okubo, S., Fogo, A., Matsusaka, T., & Ichikawa, I. ( 1 997) Targeting deletion of angiotensin type 1 B receptor gene in the mouse. Am.J .Physiol 272: F299-F304. 
60. Sugaya, T., Nishimatsu, S., Tanimoto, K., Takimoto, E., Yamagishi, T., Imamura, K., Goto, S., Imaizumi, K., Hisada, Y., & Otsuka, A. ( 1 995) 
52  
Angiotensin II t ype I a receptor-deficient mice with h ypotension and 
h yperreninemia. J .Biol.Chem. 270: 187 1 9- 187 22. 
6 1. Hughes, A. D. ( 1 9 98) Molecular and cellular mechanisms of  action of  
angiotensin II (AT I )  receptors in vascular smooth muscle. J.Hum.H ypertens. 
1 2: 27 5- 28 1. 
6 2. Ribeiro, A. B., Kohlmann, 0., Saragoca, M. A., Marson, 0., & Ramos, 0. L. 
( 1 985) The renin-angiotensin system in the control of  systemic arterial 
pressure. Drugs 30: 6- 12. 
6 3. Webb, M. L., Liu, E. C., Cohen, R. B., Hedberg, A., Bogosian, E. A., 
Monshizadegan, H., Molloy, C., Serafino, R., Moreland, S., Murphy, T. J., & . 
( 1 9 9 2) Molecular characterization o f  angiotensin II t ype II receptors in rat 
pheochromocytoma cells. Peptides 1 3: 4 9 9- 508. 
6 4. Pucell, A. G., Hodges, J. C., Sen, I., Bumpus, F. M., & Husain, A. ( 1 9 9 1 )  
Biochemical properties o f  the ovarian granulosa cell t ype 2-angiotensin II 
receptor. Endocrinology 1 28: 1 9 47- 1 9 5 9. 
6 5. de Gasparo, M., Levens, N. R., Kamber, B., Furet, P., Whitebread, S., 
Brechler, V., & Bottari, S. P. ( 1 9 9 4 )  The angiotensin II AT2  receptor subt ype. 
In: Angiotensin Receptors (Saavedra JM & Timmermans P, eds.), pp. 9 5- 1 17. 
Plenum Press, New York. 
66. Grady, E. F., Sechi, L. A., Griffin, C. A., Schambelan, M., & Kalinyak, J. E. 
( 1 9 9 1 )  Expression of A T 2  receptors in the developing rat fetus. J. Clin.Invest 
88: 9 2 1- 9 3 3. 
67. Kambayashi, Y., Bardhan, S., Takahashi, K., Tsuzuki, S., Inui, H., Hamakubo, 
T., & lnagami T. ( 1 9 9 3) Molecular cloning of  a novel angiotensin II receptor 
isoform involved in phosphotyrosine phosphatase inhibition. J.Biol.Chem. 
268: 24 5 4 3 -24 546. 
68. Ichiki, T. & Inagami, T. ( 1 9 9 5 )  Expression, genomic organization, and 
transcription o f  the mouse angiotensin II t ype 2 receptor gene. Circ.Res. 76: 
6 9 3-700. 
6 9. Saavedra, J. M., de Oliveira, A. M., Johren, 0., & Viswanathan, M. ( 1 9 96 )  
Brain angiotensin II and related receptors: new developments. Adv Exp Med 
Bio l  396: 247 -252. 
70. Matsubara, H. ( 1 9 98) Pathophysiological role o f  angiotensin II t ype 2 r ecep tor 
in cardiovascular and ren al diseases. Cir c.Res. 8 3 :  1 182- 1 1 9 1. 
53 
71. Hein, L., Barsh, G. S., Pratt, R. E., Dzau, V. J., & Kobilka, B. K. (1995) 
Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 
receptor in mice. Nature 377 : 744-747. 
72. Ichiki, T., Labosky, P. A., Shiota, C., Okuyama, S., Imagawa, Y., Fogo, A., 
Niimura, F., Ichikawa, I., Hogan, B. L., & Inagami, T. (1995) Effects on 
blood pressure and exploratory behaviour of mice lacking angiotensin II type-
2 receptor. Nature 377: 748-750. 
73. Horiuchi, M. (1996) Functional aspects of angiotensin type 2 receptor. 
Adv.Exp.Med.Biol. 396: 217-224. 
74. Csikos, T., Chung, 0., & Unger, T. (1998) Receptors and their classification: 
focus on angiotensin II and the AT2 receptor. J.Hum.Hypertens. 12 : 311-318. 
75. Brechler, V., Levens, N. R., de Gasparo, M., & Bottari, S. P. (1994) 
Angiotensin A T2 receptor mediated inhibition of particulate guanylate 
cyclase: a link with protein tyrosine phosphatase stimulation? 
Receptors.Channels 2 :  79-87. 
76. Mukhopadhyay, A. K. & Raizada, M. K. (1995) Tissue Renin-Angiotensin 
Systems Plenum Press, New York. 
77. Cassis, L. A., Saye, J., & Peach, M. J. (1988) Localization and regulation of 
rat angiotensinogen messenger RNA. Hypertension 11: 591-596. 
78. Karlsson, C., Lindell, K., Ottosson, M., Sjostrom, L., Carlsson, B., & 
Carlsson, L. M. S. (1998) Human adipose tissue expresses angiotensinogen 
and enzymes required for its conversion to angiotensin II. J Clin Endocrinol 
Metab 83: 3925-3929. 
79. Massiera, F., Bloch-Faure, M., Ceiler, D., Murakami, K., Fukamizu, A., Gase, 
J. M., Quignard-Boulange, A., Negrel, R., Ailhaud, G., Seydoux, J., Meneton, 
P ., & Teboul, M. (2001) Adipose angiotensinogen is involved in adipose 
tissue growth and blood pressure regulation. FASEB J 15 : 2727-2729. 
80. Frederich, R. C., Kahn, B. B., Peach, M. J., & Flier, J. S. (1992) Tissue­
specific nutritional regulation of angiotensinogen in adipose tissue. 
Hypertension 19: 339-344. 
81. Goodfriend, T. L. (2000) Obesity, Adipocytes, and the Renin-Angiotensin­
Aldosterone Axis. In: Adipocyte Biology and Hormone Signaling (Ntambi, J. 
M., ed.), pp. 149-157. IOS Press, Amsterdam. 
54  
82. Bloem, L. J., Manatunga, A. K., Tewksbury, D. A., & Pratt, J. H. ( 1 9 9 5 )  The 
Serum Angiotensinogen Concentration and Variants of the Angiotensinogen 
Gene in White and Black-Children. Journal of Clinical Investigation 9 5 : 948-
9 53. 
83. Cooper, R., Forrester, T., Ogunbiyi, 0., & Mu ffinda, J. ( 1 9 98) 
Angiotensinogen levels and obesity in four black populations. Journal of 
Hyper tension 16 : 57 1- 57 5. 
84. Aubert, J., Darimont, C., Sa fonova, I., Ailhaud, G., & Negrel, R. ( 1 9 97 )  
Regulation by glucocorticoids of angiotensinogen gene expression and 
secretion in adipose cells. Biochem.J. 3 28 ( Pt 2) : 70 1 -706. 
85. Sa fonova, I., Auber t, J., Negrel, R., & Ailhaud, G. ( 1 9 97 )  Regulation by fatty 
acids of angiotensinogen gene expression in preadipose cells. Biochem.J. 3 22 
( Pt 1 ): 23 5-23 9. 
86. Jones, B. H., Standridge, M. K., Taylor, J. W., & Moustaid, N. ( 1 9 97 )  
Angiotensinogen gene expression in adipose tissue : analysis of obese models 
and hormonal and nutritional control. Am J Physiol 273 : R236- R242. 
87. Saye, J., Lynch, K. R., & Peach, M. J. ( 1 9 90 )  Changes in angiotensinogen 
messenger RNA in differentiating 3 T3- F442A adipocytes. Hyper tension 1 5 :  
867-87 1. 
88. Saye, J. A ., Cassis, L. A., Sturgill, T. W., Lynch, K. R., & Peach, M. J. ( 1 989 ) 
Angiotensinogen Gene-Expression in 3 T3-Ll Cells. American Journal of 
Physiology 256 : C448- C4 5 1. 
89. Hainault, I., Nebout, G., Turban, S., Ardouin, B., Ferre, P., & Quignard ­
Boulange, A. (200 2) Adipose tissue-specific increase in angiotensinogen 
expression and secretion in the obese (fa/fa) Zucker rat. Am J Physiol 
Endocrinol Metab 282:  E 5 9-E66. 
90. Harp, J. B. & DiGirolamo, M. ( 1 9 9 5 )  Components of the renin-angiotensin 
system in adipose tissue : changes with maturation and adipose mass 
enlargement. J.Gerontol.A Biol.Sci.Med.Sci. 50 : B270-B276. 
9 1. Radin, M. J., Holycross, B. J., Sharkey, L. C., Shiry, L., & Mc Cune, S. A. 
(200 2) Gender modulates activation of renin-angiotensin and endothelin 
systems in hyper tension and heart failure. J Appl Physiol 9 2 :  93 5 -9 40. 
9 2. Engeli, S., Gorzelniak, K., Kreut z, R., Runkel, N., Distler, A., & Sharma, A. 
M. ( 1 9 9 9) Co-expression ofrenin-angiotensin system genes in human adipose 
tissue. J.Hypertens. 17 : 5 5 5- 560. 
55 
93. Kim, S., Massiera, F., Joshi, R., Anderson, B., Derfus, M., Teboul, M., 
Ailhaud, G., & Moustaid Moussa, N. (2002) Effects of angiotensinogen (agt) 
gene inactivation and high fat diet on adipocyte and lipid metabolism. F ASEB 
J 16: A604 (abs.). 
94. Darimont, C., Vassaux, G., Ailhaud, G., & Negrel, R. (1994) Differentiation 
of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose 
cells by angiotensin-II .  Endocrinology 135 : 2030-2036. 
95 . Crandall, D. L., Armellino, D. C., Busler, D. E., McHendry-Rinde, B., & Kral, 
J. G. (1999) Angiotensin II receptors in human preadipocytes: role in cell 
cycle regulation. Endocrinology 140: 154-158.  
96. Jones, B. H., Standridge, M. K., & Moustaid, N. (1997) Angiotensin II 
increases lipogenesis in 3T3-Ll and human adipose cells. Endocrinology 138 : 
1512-1519. 
97 . Kim, S., Whelan, J., Claycombe, K., Reath, D. B., & Moustaid-Moussa, N. 
(2002) Angiotensin II increases leptin secretion by 3T3-Ll and human 
adipocytes via a prostaglandin-independent mechanism. J.Nutr. 132: I 135-
1140. 
98 . AbdAlla, S., Lother, H., Abdel-tawab, A. M., & Quitterer, U. (2001) The 
angiotensin II AT2 receptor is an ATI receptor antagonist. J.Biol.Chem. 276: 
39721-39726. 
99. Mallow, H., Trindl, A., & Loffler, G. (2000) Production of angiotensin II 
receptors type one (ATI)  and type two (AT2) during the differentiation of 
3T3-Ll preadipocytes. Horm.Metab Res. 32: 500-503. 
I 00. Crandall, D. L., Herzlinger, H. E., Saunders, B. D., Zolotor, R. C., Feliciano, 
L., & Cervoni, P. (1993) Identification and Characterization of Angiotensin-II 
Receptors in Rat Epididymal Adipocyte Membranes. Metabolism-Clinical and 
Experimental 42: 511-515 . 
I 01. Crandall, D. L., Herzlinger, H. E., Saunders, B. D., Armellino, D. C., & Kral, 
J. G. (1994) Distribution of Angiotensin-II Receptors in Rat and Human 
Adipocytes. Journal of Lipid Research 35 : 1378-1385 . 
102. Cassis, L. A., Fettinger, M. J., Roe, A. L., Shenoy, U. R., & Howard, G. 
( 1996) Characterization and regulation of angiotensin II receptors in rat 
adipose tissue. Adv Exp Med Biol 396: 39-47. 
56 
103. Cranda ll, D. L., Herz linger, H. E., Saunders, B. D., & Kra l, J. G. ( 1 9 9 4) 
Deve lopmenta l aspects of the ad ipose t issue ren in-ang iotens in system: 
therapeut ic implicat ions. Drug Deve l Res 3 2: 1 1  7- 1 25. 
10 4. P interova, L., Ze lezna, B., F ickova, M., Macho, L., Kr izanova, 0., Jezova, D., 
& Zorad, S. (200 1) E levated AT I receptor prote in but lower ang iotens in I I ­
b ind ing in ad ipose t issue of rats w ith monosod ium g lutamate -induced obes ity. 
Horm Metab Res 33: 708-7 1 2. 
10 5. Enge li, S., Gorze ln iak, K., Kreutz, R., Runke l, N., D ist ler, A., & Sharma, A. 
M. ( 1 9 9 9) Co-express ion of ren in -ang iotens in system genes in human ad ipose 
t issue. J Hypertens 17: 5 5 5- 560. 
106. Mousta id, N., Standr idge, M. K., & Jones, B. H. ( 1 9 97) Angiotens in I I  
regu lat ion of ad ipose t issue metabo lism: ro le of type 2 (AT 2) receptors. 
Obes ity Research 5: 26 S (abs.). 
107. Derfus, M., Kim, S., Joshi, R., Wortman, P., & Mousta id -Moussa, N. (200 2) 
Different ia l effects of ang iotens in I I  type 2 (AT2) receptor antagon ism on 
ad ipos ity in m ice mode ls of obes ity. F A S EB J 16: A l  0 17 (abs.). 
108. Bravo, R., Somoza, B., Ru iz-Gayo, M., Gonza lez, C., Ru ilope, L. M., & 
Fernandez-Alfonso, M. S. (200 1) D ifferent ia l  Effect of Chron ic 
Ant ihypertens ive Treatment on Vascu lar Smooth Musc le Ce ll Phenotype in 
Spontaneous ly Hypertens ive Rats. Hypertens ion 37: 4e- 10. 
10 9. Carey, R. M., Howell, N. L., Jin, X. H., & S iragy, H. M. (200 1) Ang iotens in 
Type 2 Receptor-Med iated Hypotens ion in Ang iotens in Type- I Receptor ­
B locked Rats. Hypertens ion 38: 1 27 2- 1 277. 
1 10. Harry, A. & Wayner, M. J. ( 1 9 98) Losartan B locks D iazepam and Ethano l 
Effects on Air R ight ing. A lcoho l 16: 93- 9 9. 
1 1 1. Heart Fa ilure (Ch.203) ( 1 9 9 9) The Merck Manual of D iagnos is and Therapy. 
(Beers, M. H. & Berkow, R., eds.), Merck & Co., Inc .. 
1 1 2. Mousta id, N., Jones, B. H., & Tay lor, J. W. ( 1 9 96) Insu lin increases lipogen ic 
enzyme act iv ity in human ad ipocytes in pr imary cu lture. J Nutr 1 26: 86 5-870. 
1 13. Jones, B. H., Kim, J. H., Zemel, M. B., Woych ik, R. P., M ichaud, E. J., 
W ilk ison, W. 0., & Moustaid, N. ( 1 9 96) Upregu lat ion of ad ipocyte 
metabo lism by agout i prote in: poss ib le paracr ine act ions in ye llow mouse 
obes ity. Am J Phys io l 270: E 1 9 2-E 1 96. 
57 
1 1 4. Brad ford, M. ( 1 97 6) A rap id and sens it ive method for the quant itat ion of 
microgram quant it ies of prote in ut iliz ing the pr inc iple of prote in-dye b ind ing. 
Anal.B iochem. 7 2: 248- 254. 
1 1 5. Kingston, R. E. (200 1) Cs Cl pur ificat ion of RNA from t issue. In: Current 
Protocols in Molecular B iology (Ausubel, F. M., Brent, R., Kingston, R. E., 
Moore, D. D., Se idman, J. G., Smith, J. A., & Struhl, K., eds.), vol. 1, p. 4.2.5. 
John Wiley & Sons, Inc .. 
1 1 6. Bust in, S. A. (2000) Absolute quantificat ion ofmRNA us ing real-t ime reverse 
transcr ipt ion polymerase cha in react ion assays. J Mol Endocr inol 25: 1 69- 1 93. 
1 17. Kuzma, J. W .  ( 1 9 98) Bas ic Stat ist ics for the Health Sc iences,pp. 1 53- 1 5 4. 
Mayfield Publish ing Co., Mount ian View. 
1 18. Ortlepp, J. R., Breuer, J., E itner, F., Kluge, K., Kluge, R., Floege, J., Hollweg, 
G., Hanrath, P., & Joost, H.- G. (200 2) Inh ib it ion of the ren in-ang iotens in 
system ameliorates genet ically determined hyper insulinem ia. Eur J Pharmacol 
43 6: 1 4 5- 1 50. 
1 1 9. Zanella, M. T., Kohlmann, 0., & R ibe iro, A. B. (200 1) Treatment of obes ity 
hypertens ion and d iabetes syndrome. Hypertens ion 38(pt 2): 70 5-708. 
1 20. Moan, A., R isanger, T., E ide, I., & Kjeldsen, S. E. ( 1 9 9 4) The effect of 
ang iotens in II receptor blockade on insul in sens it iv ity and sympathet ic 
nervous system act iv ity in pr imary hypertens ion. Blood Press 3: 185- 188. 
1 2 1. Mass iera, F., Seydoux, J., Geloen, A., Qu ignard-Boulange, A., Turban, S., 
Sa int-Marc, P., Fukamizu, A., Negrel, R., A ilhaud, G., & Teboul, M. (200 1) 
Ang iotens inogen-defic ient m ice exh ib it impa irment of d iet- induced we ight 
ga in w ith alterat ion in ad ipose t issue development and increased locomotor 
act iv ity. Endocr inology 1 42 :  5 220- 5 225. 
58 
APPENDIX 
Table A- 1 .  Compos it ion of chow d iet. Harlan Teklad 22/5 Rodent Diet (W) 8640. 
www.teklad.com/rodent/standard /8640.htm 
G t d A I . uaran ee na 1ys1s Minerals 
Crude Protein 22.0% min. Calcium 1 . 1 3% 
Crude Fat 5.0% min. Phosphorus 0.94% 
Crude Fiber 4.5% max. Sodium 0.40% 
Chlorine 0.67% 
A vera2e N utrient C ompos1tion Potassium 1 .00% 
Protein 22 .58% Magnesium 0.24% 
Fat 5 .23% Iron 348.75 mg/kg 
Fiber 3 .94% Manganese 1 04. 1 9  mg/kg 
Ash 7.06% Zinc 78 .84 mg/kg 
Nitrogen-Free Extract 5 1 . 1 9% Copper 24.07 mg/kg 
Gross Energy 3 .82 kcal/g Iodine 2.69 mg/kg 
Digestible Energy 3 .38 kcal/g Cobalt 0.72 mg/kg 
Metabolizable Energy 3 . 1 1 kcal/g Selenium 0.26 mg/kg 
Linoleic Acid 3 .32 kcal/g 
Vitamins 
Amino Acids Vitamin A 
Arginine 1 .65% Vitamin D3 
Methionine 0.37% Vitamin E 
Cystine 0.37% Choline 
Histidine 0.52 Niacin 
Isoleucine 1 . 1 7  Pantothenic Acid 
Leucine 1 .88% P ridoxine 
Lysine 1 .29% Riboflavin 
Phenylalanine + Tyrosine 2.04% Thiamine 
Threonine 0.93% Menadione 
Tryptophane 0.29% Folic Acid 
Valine 1 . 1 7% Biotin 
Vitamin B 12  
Vitamin C 
5 9  
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Mineral Mix S 10026 
DiCalcium Phosphate 
Calcium Carbonate 
Potassium Citrate, 1 H20 
Vitamin Mix Vl000 l 
Choline Bitartrate 
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